Argenx Overview
- Year Founded
-
2008
- Status
-
Public
- Employees
-
2,009
- Stock Symbol
-
ARGX
- Investments
-
7
- Share Price
-
$970.60
- (As of Friday Closing)
Argenx General Information
Description
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
Contact Information
Website
www.argenx.comCorporate Office
- Industriepark Zwijnaarde 7
- Building
- 9052 Zwijnaarde
- Belgium
Corporate Office
- Industriepark Zwijnaarde 7
- Building
- 9052 Zwijnaarde
- Belgium
Argenx Stock Performance
As of 13-Nov-2026, Argenx’s stock price is $970.60. Its current market cap is $61B with 62.9M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $970.60 | $983.66 | $657.04 - $1.07K | $61B | 62.9M | 89.1K | $30.21 |
Argenx Financials Summary
As of 30-Sep-2026, Argenx has a trailing 12-month revenue of $5.82B.
|
In Thousands, USD |
TTM 30-Sep-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 54,974,849 | 47,947,395 | 34,354,694 | 20,434,726 |
| Revenue | 5,821,482 | 4,153,482 | 2,190,231 | 1,226,316 |
| EBITDA | 1,147,700 | (52,338) | (299,669) | |
| Net Income | 1,877,035 | 1,292,035 | 833,040 | (295,053) |
| Total Assets | 8,682,698 | 6,202,522 | 4,542,458 | |
| Total Debt | 0 | 47,160 | 39,053 | 20,000 |
Argenx Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Argenx Patents
Argenx Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026233977-A1 | Means and methods for detecting charcot-leyden crystals | Pending | 05-May-2025 | ||
| GB-202506774-D0 | Monovalent binding molecules and methods of use | Pending | 02-May-2025 | ||
| WO-2026215434-A1 | Methods of treating chronic inflammatory demyelinating polyneuropathy using liquid formulations of fcrn antagonists | Pending | 10-Apr-2025 | ||
| GB-202500659-D0 | Monovalent binding molecules and methods of use | Inactive | 17-Jan-2025 | ||
| GB-202500663-D0 | Monovalent binding molecules and methods of use | Inactive | 17-Jan-2025 |
Argenx Signals
Argenx Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Argenx Investments & Acquisitions (7)
Argenx’s most recent deal was a Merger/Acquisition with Unnatural Products for . The deal was made on 09-Nov-2026.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Unnatural Products | 09-Nov-2026 | Merger/Acquisition | Drug Discovery | ||
| Forte Biosciences | 27-Aug-2026 | Merger/Acquisition | Drug Discovery | ||
| Unnatural Products | 11-Feb-2026 | Later Stage VC | Drug Discovery | ||
| OncoVerity | 10-Dec-2024 | Early Stage VC | Drug Discovery | ||
| OncoVerity | 27-Mar-2023 | Early Stage VC | Drug Discovery |
Argenx ESG
Risk Overview
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Argenx Affiliates
Subsidiaries (6)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Argenx Uk | Gerrards Cross, United Kingdom | 2022 | |
| Argenx Germany | Munich, Germany | 2021 | |
| Argenx France | Issy-Les-Moulineaux, France | 2021 | |
| Argenx Benelux | Gent, Belgium | 2020 | |
| Broteio | Leiden, Netherlands | 2013 |
Argenx FAQs
-
When was Argenx founded?
Argenx was founded in 2008.
-
Where is Argenx headquartered?
Argenx is headquartered in Zwijnaarde, Belgium.
-
What is the size of Argenx?
Argenx has 2,009 total employees.
-
What industry is Argenx in?
Argenx’s primary industry is Biotechnology.
-
Is Argenx a private or public company?
Argenx is a Public company.
-
What is Argenx’s stock symbol?
The ticker symbol for Argenx is ARGX.
-
What is the current stock price of Argenx?
As of 13-Nov-2026 the stock price of Argenx is $970.60.
-
What is the current market cap of Argenx?
The current market capitalization of Argenx is $61B.
-
What is Argenx’s current revenue?
The trailing twelve month revenue for Argenx is $5.82B.
-
What is Argenx’s annual earnings per share (EPS)?
Argenx’s EPS for 12 months was $30.21.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process